Atea Pharmaceuticals (NASDAQ:AVIR) Earns Outperform Rating from William Blair

Atea Pharmaceuticals (NASDAQ:AVIR)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a research note issued to investors on Friday,RTT News reports. William Blair also issued estimates for Atea Pharmaceuticals’ Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($1.60) EPS.

Atea Pharmaceuticals Stock Down 0.3 %

Shares of Atea Pharmaceuticals stock opened at $2.99 on Friday. Atea Pharmaceuticals has a 12-month low of $2.75 and a 12-month high of $4.18. The company has a market capitalization of $252.54 million, a price-to-earnings ratio of -1.44 and a beta of 0.18. The firm’s 50-day moving average price is $3.15 and its two-hundred day moving average price is $3.34.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, sell-side analysts expect that Atea Pharmaceuticals will post -2.01 earnings per share for the current year.

Insider Activity

In other news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total value of $1,024,877.10. Following the completion of the transaction, the director now owns 451,897 shares of the company’s stock, valued at approximately $1,287,906.45. This represents a 44.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 17.80% of the company’s stock.

Institutional Investors Weigh In On Atea Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BML Capital Management LLC lifted its stake in Atea Pharmaceuticals by 14.4% in the 4th quarter. BML Capital Management LLC now owns 7,608,312 shares of the company’s stock valued at $25,488,000 after purchasing an additional 958,312 shares during the last quarter. FMR LLC increased its holdings in shares of Atea Pharmaceuticals by 2.8% during the third quarter. FMR LLC now owns 6,618,297 shares of the company’s stock worth $22,171,000 after buying an additional 182,174 shares in the last quarter. Tang Capital Management LLC lifted its stake in shares of Atea Pharmaceuticals by 3.9% in the 4th quarter. Tang Capital Management LLC now owns 4,788,912 shares of the company’s stock valued at $16,043,000 after acquiring an additional 181,852 shares during the last quarter. State Street Corp boosted its holdings in shares of Atea Pharmaceuticals by 0.7% during the 3rd quarter. State Street Corp now owns 1,733,486 shares of the company’s stock valued at $5,807,000 after acquiring an additional 11,566 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Atea Pharmaceuticals by 0.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,216,600 shares of the company’s stock worth $4,076,000 after acquiring an additional 9,500 shares during the last quarter. 86.67% of the stock is owned by institutional investors.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.